When your patients are diagnosed with a rare cancer type or an aggressive cancer, when chemotherapy doesn't work or when cancer comes back, OncoDEEP® can provide you with clear clinical guidance. Starting from a small sample of tumor tissue, our biomarker test is able to pinpoint the therapeutic vulnerabilities of a tumor and identify appropriate cancer treatment options in a fast turnaround.
OncoDEEP® is the most comprehensive biomarker test available on the market. It covers a wide range of cancer biomarkers carefully selected for their clinical relevance and offers a unique combination of analyses (NGS test and IHC test) that proved to maximize the clinical benefits for cancer patients.
In one simple biomarker test and in less than two weeks, OncoDEEP® can help you to:
We regularly run studies in order to evaluate the clinical impact of our comprehensive biomarker test in real life. Discover our key scientific publications published in peer-reviewed international journals.
Genomic Profiling for Patients with Solid Tumors: A Single-Institution Experience ... [READ MORE]
- Annals of Clinical Oncology
The clinical impact of using complex molecular profiling strategies in routine oncology practice ... [READ MORE]
Comprehensive biomarker testing - also known as comprehensive genomic profiling or genomic cancer test or molecular diagnostic test - is a next-generation sequencing (NGS) approach that uses a single assay to detect relevant cancer biomarkers, alterations in genes that are known to drive cancer growth, as established in guidelines and clinical trials, for therapy guidance. OncoDEEP® goes one step further by integrating tumor-specific biomarker analyses to maximize the clinical benefit for the patients.
Combining different biomarker analyses is the key to maximize the clinical benefit for the patients. A study demonstrated the clinical utility of integrating DNA, RNA and proteins in one single biomarker test. The trial was led on 1,057 advanced cancer patients in 30 countries on 4 continents that had already experienced treatment failure(s).
The OncoDEEP® comprehensive biomarker test combines NGS with IHC testing to screen for genomic alterations in the DNA and RNA (BRCA mutation, KRAS mutation, EGFR mutations, etc), genomic signatures (tumor mutational burden, homologous recombination deficiency and microsatellite instability testing) and protein biomarkers of response to targeted therapies, immunotherapy, hormonal therapy and chemotherapy. The technology is robust and accurate, and the genes of the panel were carefully selected based on their biological and therapeutical relevance.
Comprehensive biomarker testing is recommended for adults with stage 3 cancer or stage 4 cancer with solid tumors - such as metastatic breast cancer, stage 4 lung cancer, stage 3 colon cancer, metastatic prostate cancer, stage 4 ovarian cancer - or for children with brain cancer. In case of cancer of unknown primary (CUP cancer), OncoDEEP® can help decipher the primary origin of the tumor and guide clinicians towards approved therapies or drugs currently in development in oncology clinical trials.
OncoDEEP® can be used at diagnosis or at disease progression to identify biomarker-matched targeted therapies or biomarker-stratified clinical trials. It can also provide physicians with extra therapeutic guidance when chemotherapy does not work; when new biomarkers are required for second-line treatment; when cancer comes back; or when patients are diagnosed with highly aggressive cancer or a rare cancer type like a cancer of unknow primary.
OncoDEEP® can be performed on tissue biopsy, fine needle biopsy or bone marrow aspirate. The quality of laboratory test results is highly dependent on proper specimen collection and handling procedures. Our teams can guide you through our sample preparation protocol in case of any questions. All histologic samples will be reviewed by a pathologist after reception at OncoDNA.
The ISO 15189 (Medical laboratories-Requirements for quality and competence), CE-IVD (In vitro diagnostic devices complied to be sold in Europe), ISO 27001 (Information security management) and ISO 13485:2016 (Quality Management System) apply to our OncoDEEP® comprehensive biomarker test.
Ordering a solution is very simple: Just log in to OncoSHARE and select the biomarker test(s) you are interested in. If you do not have a kit for the collection of the FFPE tissue sample, we will send you one.
You can order an OncoDEEP® from anywhere in the world. In the United States, OncoDEEP® can be used for academic projects only. The test cannot be used for molecular diagnostics yet.
After FFPE tissue sample processing and data interpretation, a comprehensive and interactive report will be made available for you on OncoSHARE, our secure clinical decision support software. It will help you select the most appropriate treatments based on the unique signature of your patient's tumor. You will also be able to share the report with your colleagues.
It takes about 10 working days from the FFPE tissue sample quality control check to reporting on our clinical decision support system.
Cannot find what you are looking for? Contact us! Our Scientific Support Teams are available to answer all your questions from Monday to Friday.